Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CLARITIN HIVES RELIEF REDITAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CLARITIN HIVES RELIEF REDITAB.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs CLARITIN HIVES RELIEF REDITAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Selective inverse agonist of peripheral histamine H1 receptors, inhibiting histamine release from mast cells and basophils.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
10 mg orally once daily
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
Terminal elimination half-life of loratadine is 8.4 hours (range 3–20 hours); for its active metabolite descarboethoxyloratadine, it is 24.9 hours (range 8.8–45 hours). Clinical context: Steady-state concentrations are achieved by day 5.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Primarily renal (approximately 40% as metabolites, <1% as unchanged drug) and fecal (approximately 40% as metabolites).
Category A/B
Category C
Antihistamine
Antihistamine